Point32Health (Harvard Pilgrim and Tufts Health Plan) is implementing new prior authorization requirements for four newly FDA-approved drugs: Zevaskyn, Enflonsia, Qfitlia, and Yeztugo, effective November 17, 2025. Additionally, prior authorization criteria for Vyjuvek are being updated to clarify usage restrictions and prescriber requirements.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
01Billing team must update prior authorization workflows for new drugs Zevaskyn (J3590), Enflonsia (RSV prevention), Qfitlia (hemophilia), and Yeztugo (HIV PrEP) for Tufts Health Together members.
02Refer to MassHealth Drug List for coverage criteria.
03For Vyjuvek, ensure prescriber is documented as a specialist or specialist consult notes are provided before submitting claims.
Codes mentioned
J3590
Original notice
Point32Health medical drug program updates
point32health.org · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.